X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the...
VANCOUVER, Nov. 5, 2019 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1...
MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced the completion...
Principal investigator Dr. Jaime Guevara Aguirre, world-renowned expert on growth hormone to conduct the trial of Altsulin® (Microencapsulated Sertoli Cells) in Laron Syndrome Patients Laron Syndrome (aka Laron-type dwarfism) is a rare pediatric orphan disease...
– Over 700 patients enrolled in the T2 Protect AD Study evaluating troriluzole in symptomatic treatment of mild-to-moderate Alzheimer’s disease – Secondary and exploratory measures to assess if troriluzole can protect against, slow down, and...
Email
Text